Immage Biotherapeutics Corp.
IMMG · OTC
8/31/2016 | 8/31/2015 | 9/30/2014 | 9/30/2013 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.00 | -0.00 | -0.00 |
| FCF Yield | -148,528.75% | -99,911.76% | -3,132,647.54% | -790,009.16% |
| EV / EBITDA | 0.69 | -826.41 | 0.12 | 0.60 |
| Quality | ||||
| ROIC | -90.18% | -0.08% | 77.53% | 74.49% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.00 | 0.97 | 0.95 | 987.51 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | -211,688.55% | 99.42% | -48.50% | -253,123.74% |
| Safety | ||||
| Net Debt / EBITDA | 0.69 | -826.41 | 0.13 | 0.60 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -130.50 | 0.00 | 0.00 | 0.00 |